Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

C0690500

Ceftazidime

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Ceftazidime pentahydrate

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C22H22N6O7S2 · 5H2O
Numéro CAS:
78439-06-2
Poids moléculaire :
636.65
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

ceftazidime

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

InChI

1S/C22H22N6O7S2.5H2O/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27;;;;;/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34);5*1H2/b26-13-;;;;;/t14-,18-;;;;;/m1...../s1

Clé InChI

NMVPEQXCMGEDNH-TZVUEUGBSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Ceftazidime EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Danger

Mentions de danger

H317,H334

Classification des risques

Resp. Sens. 1 - Skin Sens. 1

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 9

1 of 9

vibrant-m

Y0000420

Cefotaxime acid

vibrant-m

P1890000

Piperacillin

Tobramycine Aminoglycoside antibiotic

Sigma-Aldrich

T4014

Tobramycine

Imipenem monohydrate ≥98% (HPLC)

Sigma-Aldrich

I0160

Imipenem monohydrate

Sulfamethoxazole European Pharmacopoeia (EP) Reference Standard

S2100000

Sulfamethoxazole

vibrant-m

A0368000

Amikacin

Méropénème trihydraté United States Pharmacopeia (USP) Reference Standard

USP

1392454

Méropénème trihydraté

Ceftriaxone sodium British Pharmacopoeia (BP) Reference Standard

BP976

Ceftriaxone sodium

Supelco

Supelco

PHR1763

Cefepime hydrochloride

Anu Kantele et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 60(6), 837-846 (2015-01-24)
More than 300 million travelers visit regions with poor hygiene annually. A significant percentage of them become colonized by resistant intestinal bacteria such as extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) and may transmit the strains to others and to medical care settings
Johanna Berkhout et al.
Antimicrobial agents and chemotherapy, 59(2), 1138-1144 (2014-12-10)
To evaluate the in vitro effects of the combination of ceftazidime and avibactam on the MICs of both compounds, checkerboard assays were performed for 81 clinical strains, including 55 Enterobacteriaceae strains (32 Klebsiella pneumoniae, 19 Escherichia coli, 1 Citrobacter freundii
S Segal-Maurer et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 28(5), 1134-1138 (1999-08-19)
Increasing prevalence of multidrug-resistant gram-negative organisms has led to a rise in clinically significant infections with these organisms and an increasing therapeutic dilemma. We present a case of a neurosurgical patient who developed ventriculoperitoneal shunt-associated ventriculitis due to ceftazidime-resistant Klebsiella
Jason A Roberts et al.
International journal of antimicrobial agents, 29(2), 117-128 (2006-12-13)
Sepsis and nosocomial infections continue to be a significant problem in intensive care, contributing heavily to mortality and prolonged hospital stay. Early and appropriate antibiotic therapy is critical for optimising outcomes. However, the emergence of highly resistant bacteria, coupled with
Sofiya N Micheva-Viteva et al.
mSystems, 5(1) (2020-02-13)
Persister cells are genetically identical variants in a bacterial population that have phenotypically modified their physiology to survive environmental stress. In bacterial pathogens, persisters are able to survive antibiotic treatment and reinfect patients in a frustrating cycle of chronic infection.
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique